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Abstract
Cognitive decline is recognized as a prevalent and debilitating symptom of multiple sclerosis
(MS), especially deﬁcits in episodic memory and processing speed. The ﬁeld aims to (1)
incorporate cognitive assessment into standard clinical care and clinical trials, (2) utilize state-
of-the-art neuroimaging to more thoroughly understand neural bases of cognitive deﬁcits, and
(3) develop eﬀective, evidence-based, clinically feasible interventions to prevent or treat cog-
nitive dysfunction, which are lacking. There are obstacles to these goals. Our group of MS
researchers and clinicians with varied expertise took stock of the current state of the ﬁeld, and
we identify several important practical and theoretical challenges, including key knowledge gaps
and methodologic limitations related to (1) understanding and measurement of cognitive
deﬁcits, (2) neuroimaging of neural bases and correlates of deﬁcits, and (3) development of
eﬀective treatments. This is not a comprehensive review of the extensive literature, but instead
a statement of guidelines and priorities for the ﬁeld. For instance, we provide recommendations
for improving the scientiﬁc basis and methodologic rigor for cognitive rehabilitation research.
Toward this end, we call for multidisciplinary collaborations toward development of bi-
ologically based theoretical models of cognition capable of empirical validation and evidence-
based reﬁnement, providing the scientiﬁc context for eﬀective treatment discovery.
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It has been 140 years since Charcot described “marked
enfeeblement of the memory” with “conceptions [that]
are formed slowly” in persons with multiple sclerosis
(MS).1 Such cognitive symptoms were overlooked during
much of the 20th century before Rao et al.2 brought
renewed attention to MS cognitive deﬁcits in Neurology®
about 25 years ago, beginning a quarter century of research
on the prevalence, expression, and neural bases of MS
cognitive dysfunction. Current work aims to incorporate
cognitive assessment into MS clinics and clinical trials,
utilize state-of-the-art neuroimaging to explicate neural
bases of deﬁcits, and develop eﬀective symptomatic cog-
nitive treatments. First, however, key knowledge gaps re-
quire attention and methodologic approaches need
improvement to advance the ﬁeld toward these goals, with
the ultimate goal of eﬀective, evidence-based, clinically
feasible interventions to prevent or treat cognitive deﬁcits.
Academic articles typically emphasize what is known, but
awareness of the unknown provides the catalyst for sci-
entiﬁc discovery.e1 As such, our international team of MS
experts identiﬁed critical gaps or ﬂaws in our knowledge
and makes recommendations for future work. This is not
a thorough review, but a joint statement of critical research
priorities.
Cognitive dysfunction due to MS
Cognitive profile
Slowed cognitive processing speed and episodic memory
decline are the most common cognitive deﬁcits in MS, with
additional diﬃculties in executive function, verbal ﬂuency, and
visuospatial analysis.2–4 Anecdotally, patients often report
diﬃculties with multitasking and word-ﬁnding, which are
sorely underinvestigated. Cognitive decline often emerges
early in disease,e2−e5 but impairment is more prevalente6 and
may diﬀer qualitatively (e.g., risk for working memory deﬁ-
citse7) among persons with progressive vs relapsing disease.
Although MS leads to deﬁcits in multiple cognitive domains
on the group level,2,3 we know little about variability in
patient-level expression of cognitive deﬁcits (e.g., patterns of
isolated vs co-occurring deﬁcits, discussed below). It is also
unknown whether deﬁcits in one cognitive domain (e.g.,
speed) contribute to dysfunction in other domains (e.g.,
memory). Although speed and memory are correlated in
Table 1 Key priorities for understanding and measuring cognitive deficits
1. Research has identified prevalent MS cognitive deficits on the group/sample level (e.g., speed, memory). Future work should examine prevalence and
expression of patient-level variability in cognitive profiles (i.e., patterns of isolated or co-occurring deficits). Also, cognitive tasks are often ascribed one
function (e.g., Symbol Digit Modalities Test and processing speed), but tasks necessarily measure other functions (e.g., incidental memory). Future research
should consider composite or latent variables as purer measures of targeted functions.
2. Cognitive abilities are assessed individually in optimal environments (i.e., single task performed while sitting in a quiet room), but many patients report
difficulty managing multiple goals simultaneously (e.g., cooking while having a conversation). Research on cognitive–motor and cognitive–cognitive
multitasking is needed to investigate real-world dual-tasking deficits. This includes validation of multitasking assessment procedures for clinical use, which
may better represent patient-reported real-world cognitive deficits.
3. It is unclear whether relationships across cognitive domains (e.g., speed, memory) are dependent or independent. Although cognitive functions are
correlated in MS, causal conclusions cannot be supported by correlations (e.g., slowed speed impairs learning), especially since cognition across domains is
also robustly correlated in healthy persons. Caution against presuming causal links among correlated functions extends to treatment expectations: it is
incorrect to assume that improvement in one function (e.g., working memory) will improve performance in a correlated function (e.g., episodic memory).
4. Substantial time and resource demands of neuropsychological assessment are obstacles to incorporation of routine cognitivemonitoring into standard of
care for patients with MS. We require validated cognitive monitoring tools that can be practically and seamlessly incorporated into the clinical MS center
setting. Tasks must be time- and resource-efficient, with easy incorporation into medical records. These may be tablet-based.
5. Cognitive impairment is typically defined as poor performance on 2 or 3 of several diverse tasks, which leads to heterogeneous and ill-defined groups of
patients with deficits in speed, memory, or other deficits. We require more precise cognitive phenotyping of patients (e.g., isolated memory impairment,
speed and memory impaired). This is critical for neuroimaging research aiming to identify neural bases of functions.
6. Prospective longitudinal designs are necessary to improve understanding of disease-related cognitive decline, rather than relying on cross-sectional
definitions of impairment. Clinically, brief cognitive assessments of all new patients would allow judgment of future decline relative to baseline. This is
a necessary step toward using cognition as a marker of disability progression and treatment efficacy.
7. Unlike interval disability metrics (e.g., Expanded Disability Status Scale), clinical meaningfulness of quantitative cognitive test scores (or change in scores) is
poorly understood. We need to identify clinically meaningful change scores to be used in treatment monitoring and clinical trials.
Abbreviation: MS = multiple sclerosis.
Glossary
BVMT-R = Brief Visuospatial Memory Test–Revised; CVLT-II = California Verbal Learning Test–II; DMT = disease-
modifying therapy; MS = multiple sclerosis; PST = Processing Speed Test; RCT = randomized controlled trial; SDMT =
Symbol Digit Modalities Test.
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Table 2 Review of cognitive tests and guidelines for cognitive assessment
Test; cognitive domain
Batteries; validated
outcomes Advantages Disadvantages Recommendations
SDMT
Cognitive processing speed
MACFIMS
BRB
MS-COG
BICAMS
MSFC
Total correct (in 90 s)
Very high sensitivity (mean d =
1.11)13: most sensitive task inMS
Good to excellent reliability
Fast and easy to administer
Well-tolerated by patients
Uniform across languages
No floor or ceiling effects
Multiple alternate forms
available
Preliminary evidence for 3–4
point clinically meaningful
change13
Other functions affected by MS
may contribute to performance
(incidental learning of symbol-
digit pairings,e14 visual scanning)
1. Highly recommended as
a cognitive monitoring tool in
clinical practice
2. Highly recommended as
a cognitive assessment tool in
research, including cross-
sectional and longitudinal
designs, and as an outcome in
clinical trials
3. SDMT should not be
considered a pure measure of
latent processing speed (due to
concomitant learning and visual
scanning requirements)
4. Incorporation of cognitive
assessment into clinical practice
with tablet- or Internet-based
processing speed tasks is a goal
for the future
PASAT
Cognitive processing speed,
working memory
MACFIMS
BRB
MS-COG
1. PASAT-3 total correct
2. PASAT-2 total correct
Moderate sensitivity (mean d =
0.63),13 but less sensitive than
the SDMT as a task of cognitive
processing speed/efficiency
Previously the most widely used
cognitive test in MS research,
including clinical trials; there is
therefore a large amount of
research PASAT data to compare
across prior studies
PASAT stimuli are auditory; most
cognitive efficiency tasks require
visual processing; PASAT may be
useful for patients with poor
vision
Reliability limited by practice
effects
Susceptible to ceiling effects
Poorly tolerated by patients
Specificity limited by multiple
factors, including math ability
and test-taking anxiety
1. Not recommended for
cognitive monitoring in clinical
practice
(The SDMT is more sensitive to
cognitive deficits,e15 and has
replaced PASAT as the MSFC
cognitive task13)
2. Not recommended for clinical
trials or designs with multiple
administrations (due to practice
effects)
3. The PASAT is a putative
cognitive processing task, which
allows results to be compared
across previous studies
4. There is a need for new
cognitive efficiency tasks using
nonvisual stimuli for patients
with visual impairment
SRT
Verbal memory
BRB
MS-COG
1. TL
2. LTS
3. CLTR
4. Delayed recall
High sensitivity (mean d = 0.86)13
Several alternate forms
(although reliability across
alternate forms needs further
validation in MS)
The selective reminding
paradigm emphasizes retrieval
of words from long-term store
(secondary memory) rather than
repetition from working
(primary) memory
There is no single authoritative
set of normative data, although
there are different sets of
published norms
SRT (like other verbal memory
assessments) is a poor candidate
for future unsupervised
assessment because tablet-
based tasks assess verbal
recognition, which is less
sensitive than verbal recall in MS
1. Recommended as a verbal
memory test for clinical and
research use, especially when
more than 2 administrations are
planned
2. The SRT has 3 validated initial
learning outcomes (TL, LTS, CLTR)
that are highly intercorrelated;
researchers are advised to identify
whichof these3measuresof initial
learning will be used
CVLT-II
Verbal memory
MACFIMS
BICAMS
1. TL
2. LDFR
High sensitivity (mean d = 0.89)13
Good age- and sex-adjusted
normative data from a large
standardization sample in the
United States
One standard and one alternate
form well-validated
There is only one alternate form
For the standard administration,
additional trials between TL and
LDFR (List B, Short Delay Free
Recall, Short Delay Cued Recall)
add time, and are required to
use published normative data
for LDFR
CVLT-II (like other verbal
memory tests) is a poor
candidate for future
unsupervised assessment, as
stated above for the SRT
1. Recommended as a verbal
memory test for clinical and
research use, especially when
robust normative data are
needed (but not whenmore than
2 administrations are required)
2. Unlike processing speed and
visuospatial memory, it will be
more challenging to develop
table- or Internet-based verbal
memory tests appropriate for
persons with MS
3. Researchers should report
whether all trials of the CVLT-II
(e.g., List B, SDFR, SDCR) were
administered or omitted
4. Recently published CVLT-III
uses the same stimuli and
administration as the CVLT-II,
but adds a new scoring option to
sum delayed recall trials (SDFR,
SDCR, LDFR, LDCR) into one
composite, which is more
reliable than LDFR alone; this
requires validation in MS
Continued
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Table 2 Review of cognitive tests and guidelines for cognitive assessment (continued)
Test; cognitive domain
Batteries; validated
outcomes Advantages Disadvantages Recommendations
BVMT-R
Visuospatial memory
MACFIMS
BICAMS
1. TL
2. Delayed recall
Very high sensitivity (mean d =
1.03)13
Good reliability and validity
Time-efficient for a memory test
(much briefer than SRT and
CVLT-II)
Well-tolerated by patients
Six well-validated alternate
forms
Good age- and sex-adjusted
normative data published in
a large standardization sample
in the United States
Severe motor impairment in
patients with advanced disease
may complicate assessment
1. Recommended as a good test
for memorymonitoring: BVMT-R
is the most sensitive memory
test within batteries designed for
persons with MS
2. Recommended for research,
including observational cross-
sectional and longitudinal
designs, and as an outcome in
clinical trials
3. The drawing/construction
requirement (although modest)
may preclude assessment in
patients with severe motor
impairment; a tablet-based (or
completely motor-free)
visuospatial task would be ideal;
however, no such task is currently
validated for persons with MS
10/36 SPART
Visuospatial memory
BRB
1. TL
2. Delayed recall
Construction/drawing is not
required, which may be helpful
in persons with severe motor
impairment; however, upper
extremity function is still needed
(patients place markers on
a grid)
Lower sensitivity (mean d = 0.48)
e16−e18 than other memory tests
for MS (BVMT-R, SRT, CVLT-II)
Reliability and good normative
data are lacking
1. Due to low sensitivity,
unknown reliability, and poor
normative data, the SPART is not
recommended as a clinical test
for memory monitoring
2. SPART is a reasonablemeasure
of spatial memory for research;
however, BVMT-R is a more
sensitive choice with established
reliability and robust norms
3. SPART may be a useful test of
spatial memory for patients with
severe drawing impairment,
although SPART still requires
placement of markers
COWAT
Verbal fluency
BRB
MACFIMS
1. Total score (3 trials
with different letters)
Moderate sensitivity (mean d =
0.54),13 but lower than other
tasks in used in MS
Validated alternate form
Time-efficient and easy to
administer
Much more related to education
and vocabulary than MS disease
burden
Unclear whether task’s
sensitivity is only explained by
processing speed
1. Not recommended for
screening or brief monitoring in
clinical practice
2. Not recommended as an
outcome for clinical trials, unless
verbal fluency is the specific
target of the intervention
3. Reasonable component of
a comprehensive
neuropsychological assessment
for research or practice
D-KEFS sorting test
Executive function
MACFIMS
1. Total correct sorts
2. Description score
Alternate form is available
(unlike most executive function
tasks)
Sensitivity is moderate (d = 0.67)
based on one large study3
(incidence of higher-level
executive dysfunction may be
lower thanprocessing speed and
memorydeficits inMS, at least as
currently measured in the clinic)
Reliability is low (which is typical
for tests of higher-level executive
function)
Administration time is long and
procedures are cumbersome
1. Not recommended for brief
monitoring in clinical practice
2. Not recommended for clinical
trials, unless executive function
is the specific target of the
intervention
3. May be useful in the context of
a comprehensive clinical
evaluation, especially when
patient performance can be
closely monitored for qualitative
problem-solving approach
JOLO
Visuospatial processing
MACFIMS
1. Total correct
Good reliability and established
validity as a visuospatial task
Alternate form is available
Easy for patients to understand
Lower sensitivity (d = 0.49)1 than
other tasks used in MS (not
necessarily a criticism of JOLO;
visuospatial ability is less
impaired than speed and
memory)
1. Not recommended for brief
monitoring in clinical practice
2. Recommended as a valid task of
visuospatial function for
comprehensive cognitive
evaluations in research or practice
3. Not recommended as an
outcome in clinical trials unless
visuospatial function is the target
of intervention
Abbreviations: BICAMS = Brief International Cognitive Assessment forMS; BRB = Brief Repeatable Battery; BVMT-R = Brief Visuospatial Memory Test, Revised;
CLTR = Consistent Long-Term Retrieval; COWAT = Controlled Oral Word Association Test; CVLT-II = California Verbal Learning Test, second edition; D-KEFS =
Delis-Kaplan Executive Function System; JOLO = Judgment of Line Orientation; LDFR = Long Delay Free Recall; LTS = Long-Term Storage; MACFIMS = Minimal
Assessment of Cognitive Function inMS;MS=multiple sclerosis;MSFC =Multiple Sclerosis Functional Composite; PASAT =PacedAuditory Serial Addition Test;
SDCR = Short-Delay Cued Recall; SDFR = Short-Delay Free Recall; SDMT = Symbol Digit Modalities Test; SPART = Spatial Recall Test; SRT = Selective Reminding
Test; TL = Total Learning.
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MS,e8 they are also robustly correlated in healthy personse9
(likely due to general abilitye10), so conclusions about direct
links between decline in speed, memory, or any function in-
dependent of premorbid ability or disease-related mediators
(e.g., cerebral atrophy) are premature and potentially mis-
leading (i.e., may encourage unfounded expectations, e.g., that
treatment of one function leads to improvement in correlated
functions) (key priorities in table 1).
We administer isolated cognitive tasks in rooms designed to
minimize distractions; however, monotasking under ideal
conditions may not capture patient-reported real-world deﬁ-
cits, especially inmultitasking: the ubiquitous demand of young
and middle adulthood to eﬀectively manage multiple simulta-
neous goals (e.g., preparing dinner while having a conversa-
tion). Indeed, evidence suggests that cognition is more
negatively aﬀected in patients with MS (relative to controls)
when performing cognitive tasks while walking (cognitive–
motor dual task),5 and in the context of environmental noise
(distraction).6 In addition to existing neuropsychological tools,
the ﬁeld should develop, validate, and utilize cognitive–
cognitive and cognitive–motor dual-task paradigms to better
address patient-reported multitasking deﬁcits, which may be
more sensitive for identifying real-world functional deﬁcits,e11,
e12 and also for predicting future decline.
Cognitive assessment
Cognitive processing speed is typically assessed as the amount
of work performed within a time limit (e.g., number of items
completed). Episodic memory is assessed as the amount of
information learned and recalled (e.g., words, visual stimuli).
Cognitive batteries developed for MS3,7,e13 include tests of
processing speed, memory, and other functions individually
administered by trained professionals. We critically reviewed
the most widely used tasks (table 2), and identiﬁed the Symbol
Digit Modalities Test (SDMT), Brief Visuospatial Memory
Test-Revised (BVMT-R), and Selective Reminding Test or
California Verbal Learning Test–II (CVLT-II) as the most
sensitive tasks currently available for cognitive monitoring in
MS. The SDMT is most sensitive, likely because good per-
formance depends on multiple functions aﬀected by MS
(mostly processing speed, but also memory and visual scan-
ning).e14 Limitations of these tasks and recommended path-
ways for improvements are noted in table 1. Patients referred
for speciﬁc clinical or research questions beyond monitoring
often require more comprehensive evaluations.
Although MS batteries are brief by neuropsychological stand-
ards, the need for even 15 minutes7 of one-on-one testing for
every patient is not practical, so cognitive monitoring is not
currently part of MS standard care. Computerized testing may
be a viable alternative to conventional paper-and-pencil as-
sessment.e19 For instance, the Processing Speed Test (PST)8 is
a tablet-based test modeled after the SDMT (and part of the
MS Performance Teste20: tablet-based Multiple Sclerosis
Functional Composite). Electronic data from tablet-based tasks
may be integrated with electronic medical records to promote
cognitive monitoring as standard care: a key innovation that
would lead to (1) better detection of cognitive decline, (2)
large datasets from representative samples to advance un-
derstanding of prevalence, time course, and risk factors for
decline, and (3) greater feasibility of postmarket studies of
disease-modifying therapy (DMT) eﬀects on cognition.
Defining cognitive impairment
Cognitive tests yield quantitative values, but it is sometimes
preferred to distill scores into classiﬁcations of “intact” or
“impaired.” Impairment is typically deﬁned as performance
below a chosen threshold (e.g., 1.5 SD below normal2,3) but
deﬁnitions of impairment have varied across studies,e21 aﬀect-
ing prevalence estimates of impairment. A large cross-sectional
study of impaired performance on the Minimal Assessment of
Cognitive Function in MS found that about 28%–52% of
patients were impaired on tests of speed (Paced Auditory Serial
Addition Test, SDMT) and 30%–55% on tests of memory
(CVLT-II, BVMT-R).3 Rates reﬂect the percentage of patients
impaired on each test at one time, but not the number of
patients impaired (1) on composite (or latent) measures of
each function (performance on single tasks is aﬀected by
multiple cognitive processes, which reduces speciﬁcity), (2) in
multiple functions (deﬁcit co-occurrence), or (3) at any point
in life (lifetime prevalence). It is also unknown whether prev-
alence of cognitive impairment has changed quantitatively or
qualitatively since the approval of newer DMT.
Studies often characterize patients as cognitively intact or
impaired based on overall performance across several tests
measuring diﬀerent cognitive functions (e.g., failure on 3
of 11 testse22), but this threshold can be met by failing
speed or memory tasks alone, or a mix of speed, memory,
and other tasks. This leads to heterogeneous “impaired”
groups of patients with diﬀerent isolated or co-occurring
cognitive deﬁcits, making interpretation of results chal-
lenging, and comparisons across studies troublesome, es-
pecially for imaging studies aiming to identify neural
correlates of impairment (which likely diﬀer across speciﬁc
cognitive domains). Future work should better character-
ize groups as impaired in isolated or combined deﬁcits
(phenotypes, e.g., memory impaired but speed intact;
speed and memory impaired), and also utilize purer
measures of each cognitive domain (e.g., latent variables or
composite domain scores).
Cognitive decline
When a patient reports a cognitive problem, he or she is
describing a change in function from a previous level;
however, the majority of cognitive research studies and
clinical evaluations are cross-sectional. Clinicians and
researchers examining single time points may miss decline
that does not cross a given threshold for “cognitive impair-
ment.” As shown (ﬁgure), patients with previous function
above the 50th percentile but declining 1.5 SDs (red arrows)
are not categorized as impaired, although such patients likely
notice and report cognitive decline. Conversely, patients
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meeting criteria for impairment may experience varying
degrees of decline before impairment (yellow arrows),
thereby adding to heterogeneity of impaired groups. Clini-
cally, baseline cognitive assessment in newly diagnosed
patients would support accurate judgment of decline from
previous function, which would be important for monitoring
cognitive disability progression and potentially evaluating
treatment eﬃcacy (see discussion of regression-based
norms,9 links.lww.com/WNL/A185; links.lww.com/WNL/
A186). Finally, the ﬁeld requires large prospective studies
with combined cognitive and MRI assessment following
newly diagnosed patients (relative to controls) over many
years to better understand how cognitive decline in each
domain progresses. A small example of such a study was
previously performed with 44 patients over 7 years.4
Clinically meaningful change
The Expanded Disability Status Scalee23 is an interval scale of
physical disability in MS ranging from 0 (no disability)
through 1 to 10 (0.5-point steps) reﬂecting disability mile-
stones (e.g., 6.0 = unilateral gait assistance), with rubrics for
clinically meaningful change.e24 There is no interval scale for
cognition in MS, and it has been challenging to validate
cognitive test score changes indicative of clinical meaning-
fulness10: an obstacle to interpretation of cognitive outcomes
in prevention and treatment research. Based on work with
timed ambulation metrics,e25 preliminary benchmarks of
clinically meaningful cognitive test values11 or change in test
values over time12 have been suggested (see reference 13 for
SDMT), with employment status often used as an objective
anchor. Ideally, we would also identify change in cognitive
scores associated with cognitive diﬃculties in everyday life.
One challenge is that patient-reported deﬁcits and cognitive
test performance are often discrepant,e26 which may be due in
part to discrepancies between laboratory cognitive tasks and
real-life cognitive demands. Note also that adequate test–
retest reliability with repeated measurementse27,e28 is an es-
sential and prerequisite step when validating meaningful
change on cognitive tasks.
Cognitive monitoring holds promise as a useful tool for dis-
ease surveillance. Indeed, cognitive decline is associated with
MRI markers of MS disease burden (see below),14 and cog-
nition can be impaired even before (or without) physical
disability.e29,e30 Emerging evidence also supports the notion of
a “cognitive relapse” whereby cognitive changes may be the
only behavioral indicator of disease activity (i.e., without
sensorimotor symptoms).15,e31 As such, brief cognitive mon-
itoring tools may identify disease activity that would otherwise
go untreated, and early cognitive deﬁcits may indicate a poor
prognosis for later disability and cerebral atrophy.e32
Neuroimaging and cognitive function
Neuroimaging research on cognition
Given the essential role of MRI in MS diagnosis and disease
surveillance, the ﬁeld of MS is at the forefront of novel and
innovative MRI technology, which provides multiple tools for
investigating cognitive deﬁcits due to MS.14 Cognitive deﬁcits
were linked to greater lesion load in early research,16 and
subsequent work shows the importance of white matter lesion
location,17 microstructural injury,18 gray matter lesions,19
cortical20 and subcortical21–23 gray matter brain atrophy, and
discrepant patterns of cerebral activation with fMRI.24
Advances in ultra-high-ﬁeld MRI,e33 myeline34 and molecu-
lar25 imaging, imaging of demyelination and remyelination,26
and nonconventional MRI techniques to assess microstruc-
tural cerebral changes27 will provide even more ways to in-
vestigate MS-related cognitive deﬁcits. A challenging but
essential next step is to integrate rich multimodality imaging
data into testable and biologically informedmodels of disease-
related cognitive deﬁcits, utilizing unique strengths of each
imaging approach. This aspirational but critical goal will re-
quire collaboration among experts in imaging modalities,
neuroscience, and cognition. Such work will inform de-
velopment of biologically plausible approaches to cognitive
rehabilitation (key priorities in table 3).
Neural bases of cognitive deficits
Neuroanatomical correlates of cognitive deﬁcits exist (e.g.,
thalamus21–23), but it is unclear whether such correlates (1) di-
rectly underlie deﬁcits, or (2) are reliable proxies of overall (or
other) cerebral damage, which mediate links to cognition. For
instance, the thalamus is highly susceptible to retrograde de-
generation,e35 and has better scan-to-scan reliability than other
structures,e36 perhaps making thalamic volume a good summary
measure of disease burden across patients with variable CNS
damage, even if thalamic change does not directly underlie
a speciﬁc deﬁcit (e.g., memory). Although reliable correlates of
cognition may be useful for prediction (discussed below),
knowledge of precise neural bases is important for identifying
therapeutic targets (e.g., neurotransmitter systems) for treat-
ment of speciﬁc deﬁcits. We need large prospective longitudinal
studies with multimodality neuroimaging to carefully document
temporal correlations of speciﬁc emerging cognitive deﬁcits with
changes in speciﬁc brain structures and functions, thereby
informing advancedmodels of disease-related deﬁcits, which will
help identify therapeutic targets. For instance, longitudinal work
may help substantiate cross-sectional links between memory
deﬁcits and hippocampal changes: atrophy on MRI,28 lesions on
double inversion recovery,29 glutamate concentration on mag-
netic resonance spectroscopy,30 abnormal activation and func-
tional connectivity on fMRI,31 and demyelination and synaptic
loss on histology.32 (See links.lww.com/WNL/A185 and links.
lww.com/WNL/A186 for information how segmentation of
hippocampal subﬁelds28,33,34 and thalamic nuclei35 may advance
understanding of cognitive deﬁcits.)
The search for speciﬁc neural correlates of distinct cognitive
functions is encumbered by the imprecision of (1) hetero-
geneously impaired groups and (2) single cognitive tasks
with multiple processing demands. MS research may be in-
formed by lifespan research using factor analytic techniques
to derive purer latent measures of speed, memory, and other
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functions.36 This approach to behavioral assessment would
complement recent factor analytic MRI analyses identifying
nonrandom patterns of regional cortical thinning due to
MS.20
Quantifying risk for future cognitive decline
Longitudinal studies have linked baseline MRI to risk for
cognitive decline, including T2 lesion volume, cerebral atro-
phy, microstructural damage, and cortical lesions.4,19,37 Al-
though labor-intensive and expensive, we need more
prospective multimodality neuroimaging studies with large
representative samples to create algorithms of risk for cog-
nitive decline. Combined with demographic, reserve,38 and
clinical variables, such algorithms should be assessed for
speciﬁcity and sensitivity in conﬁrmation samples, thereby
evaluating clinical utility. Accurate algorithms may aid in early
treatment decisions (e.g., aggressiveness of DMT), and ad-
vance research and practice of early cognitive intervention.
Note that clinical feasibility of MRI-informed risk algorithms
is currently limited by the feasibility of employing advanced
scanning sequences during clinical MRIs, as well as access to
the specialty skills needed to derive quantitative MRI metrics.
Indeed, even relatively basic metrics of total cerebral atrophy
and T2 lesion volume are rarely available to clinicians. Dif-
ferent groups are working to bridge this gap by providing
cerebral atrophy analysis services to clinicians, with the goal of
incorporating atrophy consideration into standard clinical
care.e37
Functional neuroimaging
fMRI provides a proxy of brain function, which may help
explain cognitive deﬁcits due to MS.24,31,39,40 There has been
growing concern, however, about poor reproducibility of
fMRI results, including contradictory ﬁndings of cross-
sectional MS studies (e.g., memory deﬁcits linked to lower39
and higher31 functional connectivity), and a lack of suﬃ-
ciently large longitudinal studies.41 Inconsistencies may be
due in part to diﬀerences in data collection and analysis
approaches, statistical power, and heterogeneity across pa-
tient samples. There may be ways to improve the approach
and consequent value of fMRI. First, reproducibility should
be established with large collaborative multicenter studies
using uniform methods, with out-of-sample replication of
results. Next, following a model of “registered reports” in
cognitive neurosciencee38 and trial registration (clin-
icaltrials.gov), an online repository for posting speciﬁc
study methods and hypotheses prior to data collection may
be helpful. This would yield 2 levels of evidence: exploratory
and conﬁrmatory. Although exploratory research is impor-
tant, certiﬁed conﬁrmatory results would improve conﬁ-
dence in (1) individual study results, (2) the fMRI method
in general, and (3) any future clinical utility of fMRI
techniques.
Finally, it is integral that fMRI and behavioral ﬁndings be
incorporated into working theoretical models of cognitive
dysfunction, which will provide the scientiﬁc context for
a priori hypothesis generation and testing, and model re-
ﬁnement. As discussed in the context of the functional
reorganization hypothesis (see references 42 and e39),
such models must move beyond overly simplistic views of
large network changes as either maladaptive or compen-
satory, and instead create more dynamic, biologically
plausible models informed by multimodality neuroimaging
methods.
Treatment and prevention of
cognitive impairment
Cognitive rehabilitation
Improved understanding of MS cognitive deﬁcits will inform
the nascent ﬁeld of cognitive rehabilitation, which seeks to
restore cognitive functioning (often through intensive cog-
nitive training programs) or teach compensatory strategies to
attenuate the deleterious eﬀect of refractory cognitive deﬁcits
on quality of life. Eﬃcacy for such interventions in MS is
currently low, inconclusive, or preliminary, as concluded by
(1) a Cochrane review of 20 randomized or quasi–
randomized controlled trials (RCTs) of behavioral inter-
ventions to improve cognition in MS (data search up to July
2013),43 (2) a separate systematic review of 33 original in-
tervention studies (including nonrandomized trials, search up
to January 2014),44 and (3) a Cochrane review of 15 in-
tervention trials speciﬁcally targeting memory (search up to
June 2015).45 In addition to small sample sizes, quality of
studies was limited by several methodologic ﬂaws (e.g., poor
blinding, unvalidated outcomes). Note also that a Cochrane
review of symptomatic pharmaceutical treatment of memory
deﬁcits in MS revealed only 7 RCTs (data search up to June
Figure Cognitive decline from previous functioning
About half of persons with multiple sclerosis are considered cognitively
impaired in prevalence studies, which is based on performance below
a chosen threshold (yellow arrows crossing −1.5 SDs). As illustrated, how-
ever, patients may experience and report notable decline from previous
function without crossing the threshold into impairment (red arrows), al-
though such decline likely affects real-world functioning. For example, the
uppermost red arrow represents a person with above average cognition
prior to disease onset (84th percentile). Despite a decline of 1.5 SD, this
person’s current performance is within the average range (dark blue shaded
area), and she or he would be categorized as cognitively intact in research
studies. Clinically, this person may be told that he or she does not have
impairment, which conflicts with his or her real experience of decline.
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2013),46 with no evidence for eﬃcacy (key priorities in
table 4).
We require a science of cognitive rehabilitation capable of
yielding high levels of evidence. Toward this end, we must
develop theoretical models of MS-related cognitive dysfunc-
tion and identify mechanisms of action to treat deﬁcits, fol-
lowed by large RCTs with validated outcomes. This rigorous
pathway to high-level evidence is required by regulatory
agencies before approving clinical use of new agents (e.g.,
DMTs), and perhaps similar regulation should be considered
for cognitive rehabilitation. There is less industry funding to
perform large labor-intensive RCTs of cognitive rehabilitation
interventions; however, grant funding may be sought for
multicenter collaborations, which may increase sample size
and representativeness. Finally, standards for a priori report-
ing of methods must be upheld for cognitive rehabilitation
RCTs, including greater transparency for outcomes (e.g.,
speciﬁc scores on speciﬁc tests registered on clinicaltrials.gov,
rather than nonspeciﬁc references to “cognition” or “memory
tests”). Cognitive rehabilitation researchers are directed to
Simons and colleagues47 for a thorough discussion of essential
guidelines for the conduct of high-quality cognitive in-
tervention trials.
Theoretical models
As proposed for the ﬁeld of rehabilitation generally,48 we must
identify mechanisms of action and active ingredients of cog-
nitive rehabilitation interventions. For instance, if we discover
that a training program improves memory by strengthening
hippocampal structure and function, we may also consider
other interventions targeting hippocampal health; e.g., aero-
bic exercise,e40 intellectual enrichment,e41 glucose control,e42
and stress management.e43 Availability of alternative treat-
ments is important when considering clinical feasibility, as
time-consuming, expensive cognitive training programs
may be feasible for some patients, whereas other patients will
be more likely to engage in alternative approaches (e.g., ex-
ercise). A model should also distinguish diﬀerent types of
rehabilitation approaches and goals: (1) restorative inter-
ventions aiming to bolster underlying neurophysiologic bases
of memory, vs (2) compensatory approaches aiming to im-
prove memory through strategies (e.g., mnemonics) or aids
(e.g., diaries; see discussione44,e45). This has implications for
trial outcomes: e.g., given that compensatory strategies only
work when patients use them (like a cane for walking), we
should not assess treatment eﬃcacy with standardized
memory tests that prevent or encumber strategy usage (as
standardized administrations may prevent compensatory
strategy usage).
Secondary structural and functional neuroimaging out-
comes may help identify mechanisms of action for inter-
ventions49 and identify markers of capacity to beneﬁt from
interventions (responders vs nonresponders). This may
help hone treatments and inform new treatment de-
velopment, and identify subgroups with residual capacity to
respond to interventions. Like cognitive outcomes, speciﬁc
neuroimaging outcomes should be stated (registered) prior
to data collection, or otherwise be described as exploratory.
Finally, the goal of enhancing brain structure and function
in biologically plausible and lasting ways likely requires
greater “doses” (duration and intensity) of interventions
than is typically performed, and perhaps combined thera-
pies with potentially synergistic eﬀects (e.g., training plus
neurostimulatione46).
Primary prevention
We should also promote primary prevention of cognitive
decline, in part through interventions and healthy lifestyles
that promote brain maintenance.50,51 Candidate modiﬁable
lifestyle factors to build or maintain brain reserve include
Table 3 Key priorities for neuroimaging investigations of cognitive deficits
1. Researchers should aim tomake the challenging but important distinction between (1) neuroimaging correlates and (2) neural bases of cognitive deficits, as
these may not overlap. Strong correlates of cognition may ultimately be useful for prediction, but knowledge of precise neurobiological bases of deficits will
be important for identifying specific therapeutic targets (e.g., neurotransmitter systems). Multimodal imaging and experimental paradigms incorporated into
biologically plausible models of MS-related deficits may facilitate discovery of precise neurobiological bases/treatment targets.
2. Investigation of isolated cognitive constructs (e.g., memory) rather than heterogeneous composites of multiple cognitive domains is necessary to advance
models of precise neuroanatomical and neurophysiologic bases of disease-related cognitive deficits. The use of domain-specific composite scores or latent
variables would be useful.
3. Development of multivariate models (incorporating demographic, neuroimaging, and clinical variables) to better predict decline in separate cognitive
domains is needed to develop clinically useful risk algorithms. The importance of risk and protective factors is not a new idea in itself; however, the
development of clinically useful algorithmic tools to predict decline and inform treatment would be novel and important for the field.
4. We require clinically feasible tools or services for the quantification of disease burden fromMRIs in the MS clinic, including T2 lesion volume and cerebral
atrophy.With training, cortical lesions and cortical thinningmayalso be quantified.Once available, suchmetricsmay improve disease surveillance and clinical
decision-making. Also, quantification of lesion volume and cerebral atrophy from clinical MRIs within large representative samples would yield rich datasets
for new research opportunities.
5. We need to address the reproducibility problem in fMRI work, perhaps by promoting multicenter collaborations with comparable methods, but also by
registering a priori hypotheses. This would yield 2 levels of fMRI evidence: exploratory and confirmatory. Exploratory evidence is important for novel
discoveries, but confirmatory evidence is needed for model building and validation of fMRI as a valid research and clinical tool.
Abbreviation: MS = multiple sclerosis.
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physical exercise,52 mentally active lifestyles (cognitive
reserve),38,53 management of cardiovascular risk factors54 and
other comorbidities,55 smoking cessation,56 and stress man-
agement.57 Research should strive to understand mechanisms
of action for protective factors (e.g., moderating MS disease
activity vs maintaining brain volume in a non-disease-speciﬁc
way). Studies typically examine few risk or protective factors
at a time, but we need larger studies of numerous factors in the
same large cohort to understand (1) whether and to what
extent each risk or protective factor makes independent
contributions to an outcome, (2) mediating or interactive
eﬀects among diﬀerent factors on an outcome, and (3) how
(1) and (2) diﬀer across outcomes (e.g., speed, memory). We
also need to raise the level of evidence (e.g., RCTs) linking
lifestyle factors to cognition, and explore additional variables
(e.g., diete47,e48). (DMTs as protective factors are discussed
in links.lww.com/WNL/A185 and links.lww.com/WNL/
A186.)
Holistic approach to cognitive rehabilitation
Eﬀective intervention will require patient understanding,
motivation, and compliance, as well as willingness by clini-
cians to consider the unique circumstances of individual
patients (e.g., family/social support, comorbidities, goals).
Ideal holistic rehabilitation approaches consider cognitive,
emotional, and psychosocial aspects of each patient’s life.58
Patient education may promote metacognition and active
participation. For instance, therapeutic feedback after neu-
ropsychological assessments may support understanding of
one’s cognitive proﬁle, and aid patients in ﬁnding ways to
maximize cognitive strengths and minimize weaknesses in
daily life. Education on cognitive deﬁcits and factors aﬀecting
cognition (e.g., sleep, medications, mood, fatigue) may pro-
mote active participation and a positive sense of agency
among patients.59 Indeed, preliminary results on structured
metacognitive training with peer support are encouraging.e49
To advance this holistic approach, research is also needed to
better understand shared neural bases for mood and cognitive
dysfunction,60 which may yield new directions for cognitive
treatments. Finally, treatment will likely be most eﬀective
when tailored to a patient’s speciﬁc deﬁcit in the context of his
or her degree of spared cognition and cerebral reserve. For
instance, a memory deﬁcit due to diﬀuse white matter lesions
may require a diﬀerent treatment approach than a deﬁcit
secondary to a focal hippocampal lesion. Consideration of
distinct subtypes of deﬁcits requiring distinct treatment
approaches (i.e., precision medicine) is a key challenge and
opportunity for the future.
Discussion
The literature on cognition in persons with MS has grown
exponentially over the last 25 years, and cognitive dysfunction
is now recognized as a core symptom of MS. Herein we
discussed obstacles and challenges for the ﬁeld and made
recommendations for moving research forward. The next 25
years will bring redoubled collaboration across centers and
areas of expertise, and utilize advances in neuroimaging,
genetics/epigenetics, and validation of cognitive endpoints.
Collaborations and advanced methods are invaluable, but the
real science of cognition and cognitive rehabilitation in MS
will rely on multidisciplinary collaborations toward de-
velopment of biologically based theoretical models of
Table 4 Key priorities for treatment and prevention of cognitive deficits
1. Rigorous research designs are required to produce higher levels of evidence for cognitive rehabilitation research, including multicenter double-blind
randomized controlled trials, with clear and specific a priori outcomes. Essential guidelines for the conduct of high-quality cognitive intervention trials have
been discussed by Simons and colleagues.47 Adherence to these recommendations by investigators, post hoc reviewers, and journal editors will greatly
improve trial quality and the science of MS cognitive rehabilitation.
2. We require theoretical frameworks to build a science of cognitive rehabilitation in MS, with biologically plausible mechanisms of action, and clear
delineation of rehabilitation approaches (e.g., restorative vs compensatory). Models will be informed by greater understanding of neural bases of cognitive
function. The goal of changing brain structure and function in plausible and lasting ways likely requires greater “doses” (duration and intensity) of
interventions, or combined therapies with synergistic effects.
3. Structural and functional neuroimaging outcomes may explore mechanisms of action for interventions; however, when used as trial endpoints, specific
hypotheses of treatment effects on neuroimaging outcomes should be stated a priori. Otherwise, such outcomes should be considered exploratory evidence
requiring confirmation in a subsequent trial.
4. Observational research has identified candidate modifiable lifestyle factors that may protect against cognitive decline, including mental activity, physical
exercise, and stress management. Research is needed to (1) establish causal relationships between protective factors and outcomes, including utilization of
RCTs, (2) examine the unique and possibly differential contributions of each protective (or risk) factor to each individual cognitive outcome (speed, memory),
as well as potential synergistic effects (interactions) among protective factors, and (3) exploremechanisms of action for different protective (or risk) factors (e.
g., moderating MS disease activity itself vs building/preserving reserve).
5. Any promising cognitive interventionsmust be implemented in the context of a patient’s life. A holistic approach tomatch treatmentwith a patient’s unique
circumstances, priorities, and abilities is necessary in future translational research and practice. That is, interventions will only be effective if they are clinically
feasible for an individual patient.
6. Cognitive rehabilitation interventionsmay bemost effective when tailored to a patient’s specific deficit, whichmay differ within the same cognitive domain
(e.g., memory deficit secondary to diffuse whitematter lesions vs focal hippocampal lesion). Consideration of distinct subtypes/etiologies of deficits requiring
distinct treatment approaches (i.e., precision medicine) is both a challenge and a potential opportunity for rehabilitation.
Abbreviations: MS = multiple sclerosis; RCT = randomized controlled trial.
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cognition capable of empirical validation and evidence-based
reﬁnement, providing the necessary context for eﬀective
treatment discovery.
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